← Back to headlines
AtaiBeckley Aims for Q2 Start of Phase 3 Depression Trial
AtaiBeckley is targeting a Q2 start for its Phase 3 clinical trial for depression, signaling advancements in its drug development pipeline. The company is progressing with its research efforts.
12 May, 13:22 — 12 May, 13:22
Sources
Showing 1 of 1 sources
